This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rowinsky, E. K. Search for Related Content PubMed PubMed Citation Articles by Rowinsky, E. K.

Weekly Topotecan: An Alternative to Topotecan’s Standard Daily x 5 Schedule?

Institute for Drug Development, The Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, Texas, USA

Correspondence: Eric K. Rowinsky, M.D. (Z414), Director, Clinical Research, Institute for Drug Development, 4th Floor, Zeller Building, 7979 Wurzbach Road, San Antonio, Texas 78229, USA. Telephone: 210-616-5946; Fax: 210-692-7502; e-mail: erowinsk{at}saci.org

Relapsed ovarian cancer and small cell lung cancer are frequently treated with topotecan (Hycamtin^®), for which the standard dose and schedule are 1.5 mg/m² daily for five consecutive days every 3 weeks. Clinical experience has shown that this dose and schedule may be too toxic for some patients, especially those who have been heavily pretreated with platinum-based therapeutics, and it has been suggested that starting doses of topotecan be reduced to 1.0-1.25 mg/m²/d. Recently, multiple clinical trials have begun to evaluate the feasibility and preliminary antitumor activity of an alternative schedule based on weekly administration of topotecan. The potential benefits of weekly administration include not only reduced toxicity without significant compromise of antitumor activity, but also greater patient convenience and quality of life and greater potential for developing new topotecan-containing combination therapies. This report reviews the rationale for a weekly schedule, as well as a growing base of emerging clinical data. These preliminary data suggest that weekly topotecan is active; further evaluations are planned to confirm the activity and therapeutic index and to determine optimal dosing of a weekly schedule.

Key Words. Chemotherapy • Topotecan • Weekly administration

This article has been cited by other articles:

				J. R. Eckardt Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer Oncologist, December 1, 2004; 9(suppl_6): 25 - 32. [Abstract] [Full Text] [PDF]

				S. Wadler, D. E. Levy, S. T. Lincoln, G. S. Soori, J. C. Schink, and G. Goldberg Topotecan Is an Active Agent in the First-Line Treatment of Metastatic or Recurrent Endometrial Carcinoma: Eastern Cooperative Oncology Group Study E3E93 J. Clin. Oncol., June 1, 2003; 21(11): 2110 - 2114. [Abstract] [Full Text] [PDF]

				R. Morris and A. Munkarah Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 29 - 35. [Abstract] [Full Text] [PDF]